$85m fund supports monoclonal antibody for fibro-inflammatory disorders
Antibody therapeutics company Lassen Therapeutics has closed an oversubscribed $85 million Series B financing. The proceeds will fund a Phase II study in thyroid eye disease (TED) with the company’s monoclonal antibody LASN01 and the continued development of LASN500 for cancer. The clinical programme… Read More